Entrada Therapeutics, Inc.
TRDAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 12, 2026 | Roth Capital | $11.00(+43%) | $7.67 | TheFly | |
| Jun 8, 2026 | Guggenheim | $17.00(+167%) | $6.37 | TheFly | |
| May 8, 2026 | Roth Capital | $10.00(+51%) | $6.63 | TheFly | |
| Feb 10, 2026 | Guggenheim | $20.00(+85%) | $10.82 | TheFly | |
| Jan 28, 2026 | Oppenheimer | Kostas Biliouris | $21.00(+91%) | $11.00 | TheFly |
| Nov 6, 2025 | Roth Capital | $13.00(+87%) | $6.95 | TheFly | |
| Feb 28, 2025 | Roth Capital | $23.00(+93%) | $11.94 | TheFly | |
| Nov 6, 2024 | H.C. Wainwright | Boobalan Pachaiyappan | $20.00(+11%) | $18.02 | StreetInsider |
| Jun 25, 2024 | H.C. Wainwright | Raghuram Selvaraju | $18.00(+26%) | $14.24 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Jun 8, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 8, 2026 |
| Oppenheimer | maintain | Outperform | Apr 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2024 |
| Oppenheimer | maintain | Outperform | Nov 6, 2024 |
| Oppenheimer | maintain | Outperform | Aug 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2023 |
| Goldman Sachs | maintain | Neutral | Nov 8, 2022 |
| Goldman Sachs | maintain | Neutral | Aug 16, 2022 |
| Goldman Sachs | maintain | Neutral | May 24, 2022 |
| Evercore ISI Group | maintain | Outperform | Nov 24, 2021 |
| Goldman Sachs | maintain | Neutral | Nov 23, 2021 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-1.01| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.94 | $-0.98 | $905.0K | $2.3M |
| Aug 5, 2026 | $-1.01 | $-1.05 | $898.0K | $2.2M |
| May 7, 2026 | $-0.95 | $-1.06 | $875.0K | $2.9M |
| Feb 26, 2026 | $-0.94 | $-1.32 | $1.3M | $7.4M |
| Nov 6, 2025 | $-1.06 | $-1.04 | $1.6M | $8.5M |
| Aug 6, 2025 | $-1.04 | $-0.86 | $1.9M | $7.8M |
| May 8, 2025 | $-0.42 | $-0.78 | $20.6M | $9.8M |
| Feb 27, 2025 | $0.03 | $-0.66 | $37.4M | $13.1M |
News
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.06 per share a year ago.
-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – -- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg -- -- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 -- -- Expected cash runway extended into Q4 2027 …
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Insider and Institutional Ownership 86.4% of Entrada
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascendin…
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and function…
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, with downside to $4–$4.60 if higher dosing fails to deliver.
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystr…
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,583,333 shares of the company's stock, valued at approximately $19,013,000. BlackRock Inc. owned 6.65% of Entrada Therapeutics at
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company's common stock to eight newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026.